Explores how boron influences RNA chemistry in pre-cellular environments, suggesting new pathways for life's origins.
Life almost certainly began as chemistry long before the appearance of cells and genes. In this pre-cellular phase (Chemical Life), metastable reaction networks would have required mechanisms that increase the persistence of fragile intermediates, bias reaction pathways, and enable stepwise accumulation under non-equilibrium cycling. Here we propose that boron (B), through pH-dependent speciation and reversible interactions with polyhydroxylated substrates, can act as an effective chemical scaffold for ribonucleic acid (RNA)-relevant precursor chemistry. Under mildly alkaline and low water activity regimes (e.g., films, gels, evaporitic/brine microenvironments, and mineral interfaces), borate can reversibly associate with cis -diol motifs in sugars, favoring furanosyl forms (including ribose) and reducing degradative side reactions; in related settings, borate–sugar interactions can also help bias phosphate-transfer reactions toward improved regioselectivity. These roles address key constraints on prebiotic sugar persistence and phosphate availability/reactivity in bulk water. To operationalize when such effects are most plausible, we introduce the Boron Availability Index (BAI) as a heuristic, test-design metric integrating B speciation with environmental modifiers (water activity, ionic strength/competition, mineral buffering, and transport/exchange). We highlight an intermediate proposed test window (BAI ≈0.2–0.4, heuristic) where sugar stabilization, phosphorylation directionality, and network persistence can be jointly evaluated by controlled variation of physicochemical parameters. We therefore frame the Boron Theorem as a conditional, falsifiable constraint within RNA world-compatible pathways: environments that sustain B in a reactive, water-soluble form (borate) under suitable geochemical context are more likely to support Chemical Life by increasing the persistence and directional reactivity of ribose–phosphate intermediates.
No takes yet. Share an insight, caveat, or question.
Mogoşanu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: